Yuankai Shi

44PUBLICATIONS
43CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersInnate immunityHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (44)

|Jun 26, 2026
Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study.

|Jun 12, 2026
Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study.

|Apr 02, 2026
Rezivertinib in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR Study.

Sheng Yang, Yanqiu Zhao, Meili Sun

|Feb 15, 2026
DSG2+ Cancer Stem Cells Co-Located With FAP+ Myofibroblasts in the Tumor Boundary That Determines the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer.

Guangyu Fan, Le Tang, Tongji Xie

|Aug 25, 2025
Multiomics and Single-Cell Insights Reveal a Lysophosphatidic Acid-Mediated Resistant Mechanism to Third-generation EGFR-TKI in Non-Small Cell Lung Cancer.

Ruyun Gao, Ning Lou, Sheng Yang

|Aug 11, 2025
Efficacy and Safety of Afatinib Plus Bevacizumab as First-Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial.

Huiyang Shi, Miaohan Wang, Junling Li

Pageof 8

Frequent Collaborators

6 joint publications

Xiaohong Han

3 joint publications

Haohua Zhu

3 joint publications

Le Tang

3 joint publications

Jiarui Yao